ClinicalTrials.gg
Not yet recruitingNCT06687174Updated Nov 18, 2024

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

A Phase 2 interventional study of MY008211A tablets and MY008211A tablets matched placebo in IgA Nephropathy (IgAN), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Wuhan Createrna Science and Technology Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
60th of 109
72 · median 84
Started
2024
with 11 others
Phase 2
27 of 127
14 open now
Primary completion
2026-06
later than 15 of 72 live
Registered
77th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 60th largest by planned enrollment of the 109 interventional ones that give a count, is one of 12 that started in 2024, is one of 27 in phase 2, reaches primary completion later than 15 of the 72 other live ones, and was the 77th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

Efficacy and safety of MY008211A in IgAN patients

Read the detailed description

This was a multicenter, randomized, double-blind, dose-ranging, parallel-group study. Two doses of MY008211A (200mg, 400mg) were compared with placebo. The study comprised a screening period of this study for 90 days, an efficacy observation period for 24 weeks, a long-term study for 80 weeks, and a follow-up period for 2 weeks.

03

Conditions studied

  • IgA Nephropathy (IgAN)

Keywords

  • kidney disease
  • Primary glomerular disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 18 and ≤ 75 years of age at Screening.
  2. Estimated (eGFR) ≥30 mL/min/1.73m2.
  3. Subjects with a -confirmed diagnosis of IgAN.
  4. Urine protein ≥0.75 g/24h from a 24h urine collection.
  5. All patients must have been on stable supportive care including a maximally tolerated dose or approved maximal dose of ACEi or ARB therapy for at least 90 days prior to the first administration of study drug.
  6. Subjects who received SGLT2i must have been on a stable treatment with the maximum allowed or tolerated dose prior to the first administration of study drug.
  7. Vaccination against Neisseria meningitidis(MenACWY) is required within 3 years.
  8. Vaccination for the prevention of S. pneumoniae is required within 5 years.

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure >130 mm Hg or diastolic blood pressure >80 mm Hg.
  2. Presence of any secondary IgAN.
  3. Presence of rapidly progressive glomerulonephritis.
  4. Presence of other chronic kidney diseases.
  5. Patients with a diagnosis of type 1 or type 2 diabetes mellitus.
  6. A history of invasive infections caused by encapsulated bacteria, e.g., meningococci or pneumococci.
  7. Patients previously treated with agents exposure within 90 days prior to start of study drug dosing.
  8. Patients previously treated with traditional Chinese medicine containing immunosuppressive ingredients within 90 days prior to start of study drug dosing.
  9. Patients who had been treated with any systemic within the 180 days before treatment ≥20 mg/d for primary IgAN indication.
  10. Patients who previously have received biologic agent or monoclonal antibodies prior to start of study drug dosing within 5 half-lives or 30 days (whichever is longer).
  11. Patients who have received live/attenuated vaccines within the 4 weeks prior to randomization, or plan to receive during the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    MY008211A 200 mg BID

    200 mg taken twice a day.

    Drug: MY008211A tablets

  • Experimental
    MY008211A 400 mg BID

    400 mg taken twice a day.

    Drug: MY008211A tablets

  • Placebo comparator
    Placebo

    Matching placebo to MY008211A taken twice a day.

    Drug: MY008211A tablets matched placebo

Interventions

  • MY008211A BID

  • DrugMY008211A tablets matched placebo

    Matching placebo to MY008211A taken twice a day.

06

What researchers measure

Primary outcomes

  1. The ratio of urine protein to creatinine concentration ratio (UPCR based on 24h urine collection, 24h-UPCR) relative to baseline at Week 12.

    Participants collected their urine over a 24-hour period.

    Time frame: Week 12

Secondary outcomes

  1. The ratio of 24 h-UPCR relative to baseline at each visit during treatment period except Week 12.

    Participants collected their urine over a 24-hour period.

    Time frame: up to 24 weeks

  2. The ratio of 24-hour urine protein excretion (24 h-UPE) relative to baseline at each visit during treatment period.

    Participants collected all of their urine over a 24-hour period.

    Time frame: up to 24 weeks

  3. The ratio of 24-hour urine albumin (24 h-UA) relative to baseline at each visit during treatment period.

    Participants collected all of their urine over a 24-hour period.

    Time frame: up to 24 weeks

  4. The ratio of 24-hour urine albumin to creatinine concentration ratio (24 h-UACR) relative to baseline at each visit during treatment period.

    Participants collected all of their urine over a 24-hour period.

    Time frame: up to 24 weeks

  5. Change from baseline in serum creatinine at each visit during treatment period.

    Serum creatinine

    Time frame: up to 24 weeks

  6. Change from baseline in estimated glomerular filtration rate (eGFR) at each visit during treatment period.

    eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

    Time frame: up to 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Jun 2026, 17 months later.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 13, 2024
StartEst.
Dec 31, 2024
Primary completionEst.
Jun 15, 2026
CompletionEst.
Jan 31, 2028
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06687174
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Dec 31, 2024 (estimated)
Primary completion
Jun 15, 2026 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 18, 2024

Study contacts

Donghui Li, PH.D.
Contact
lidonghui@createrna.com
(+86)027-68788900
Hong Zhang, PH.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lanoracopan

Start the discussion